Langli Biology Listed on National Equities Exchange and Quotations (NEEQ), Endodontic Treatment Materials Revenue Reached 45.8832 Million Yuan in 2025

Source: Longli Biotech Announcement on Stock Listing

DentalGoodNews｜Langli Biomedical (Wuhan) Co., Ltd. issued a cautionary announcement that its shares were listed on the Basic Tier of the National Equities Exchange and Quotations (NEEQ) starting September 23, 2026, with transfer conducted via call auction, under the securities abbreviation "Langli Biomedical" and securities code 875256.

Public information shows that Langli Biomedical was founded in 2009 and is a national high-tech enterprise specializing in the research and development, production, and sales of dental materials. Its main products focus on the segmented field of endodontic treatment materials, covering product categories such as root canal lubricating materials, root canal disinfecting materials, and root canal obturation and restoration materials.

Source: Public Transfer Prospectus (Draft Application)

In terms of financial data, according to the public transfer prospectus, the company's operating revenue in 2025 was 69.5603 million yuan, an increase of 14.94% compared with 2024; net profit attributable to shareholders of the parent company in 2025 was 39.9949 million yuan, a year-on-year increase of 10.99% compared with 2024; the gross margin in 2025 was 80.83%, a slight decrease from 81.69% in 2024; the debt-to-asset ratio in 2025 was 12.16%, lower than 12.97% in 2024.

Source: Public Transfer Prospectus (Draft Application)

In terms of product structure, the public transfer prospectus shows that Langli Biomedical's main business revenue is primarily driven by endodontic treatment materials. In 2025, revenue from this category of products reached 45.8832 million yuan, accounting for 65.96% of main business revenue, making it the company's most important source of revenue; revenue from disinfection and antibacterial products reached 22.4142 million yuan, accounting for 32.22%.

In 2025, the company's main business revenue increased by 8.9076 million yuan compared with 2024, up 14.72% year on year, mainly benefiting from the continued expansion of the oral hygiene industry market scale driven by heightened public awareness of oral hygiene; during the reporting period, sales to the company's top five customers increased by 9.0254 million yuan year on year, and revenue from main products maintained growth over the past two years.

Source: Public Transfer Prospectus (Draft Application)

In terms of R&D investment, the company's R&D expenses in 2025 were 3.1688 million yuan, accounting for 4.56% of operating revenue, a decrease from 3.3674 million yuan in 2024 (accounting for 5.56% of operating revenue); Net Cash Flow from Operating Activities in 2025 was 46.7962 million yuan, an increase of 23.93% from 37.7609 million yuan in 2024.

Source: Public Transfer Prospectus (Draft Application)

In terms of sales model, the public transfer prospectus shows that the company adopts a sales model primarily based on distribution and supplemented by direct sales. Revenue from the distribution model accounted for 99.05% and 99.26% of main business revenue in 2024 and 2025, respectively. During the reporting period, the combined sales revenue from the company's top five distributors accounted for 44.02% and 51.27% of operating revenue, respectively.